Evidence mapPaperPMID 39901468Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2025

Effect of the COVID-19 pandemic on diabetic retinopathy and referral levels in the English National Health Service Diabetic Eye Screening Programme.

P H Scanlon, C F E Norridge, D Prentis, N Holman, P Rankin, J Valabhji

Abstract read
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

P H ScanlonGloucestershire Retinal Research Group (GRRG), Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.ORCID https://orcid.org/0000-0001-8513-710X
C F E NorridgeGloucestershire Retinal Research Group (GRRG), Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.ORCID https://orcid.org/0000-0002-4548-3902
D PrentisNHS England, London, UK.
N HolmanDepartment of Epidemiology and Bio-Statistics, Imperial College, London, UK.ORCID https://orcid.org/0000-0002-7432-5786
P RankinNHS England, London, UK.
J ValabhjiNHS England, London, UK.ORCID https://orcid.org/0000-0001-9756-4061

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim was to determine the effect of the COVID-19 pandemic on diabetic retinopathy and referral rates in the English National Health Service (NHS) Diabetic Eye Screening Programme (DESP).

methodsNon-patient identifiable data are submitted centrally from the 57 regional centres in the NHS DESP on a quarterly basis and analysed using STATA, comparing 01/04/2019-31/03/2020 and 01/04/2021-31/03/2022. Patient characteristics were analysed from National Diabetes Audit (NDA) data.

resultsThere were 2,274,635 grades from the 57 centres in 2019-2020 and 2,199,623 grades in 2021-2022. The proportion of eyes with referable DR increased from 3.1% in 2019-2020 to 3.2% in the 2021-2022 NHS year (p < 0.01) with a small increase in the level of non-referable DR from 24.6% to 24.8% (p < 0.01). The median proportion of ungradable eyes in 2019-2020 was 2.6% (IQR: 2.3% to 3.3%) increasing to 3.1% (IQR: 2.5% to 3.7%) in 2021-2022. NDA data demonstrated that the proportions with type 1 diabetes receiving eye screening were higher in the latter year (8.3% vs. 7.3%).

conclusionThe COVID-19 pandemic was associated with small increases in referable retinopathy rates from 3.1% to 3.2%, non-referable DR from 24·6% to 24.8% and an increase in the ungradable image rate from 2.6% to 3.1%, the latter increase possibly being caused by untreated cataract during the pandemic. Risk stratification of invitations in the recovery period was believed to have contributed to keeping the referable rates low and supports a similar approach in extension of the screening interval for low-risk groups.

Indexed as

COVID-19Diabetic RetinopathyMass ScreeningReferral and ConsultationAgedEnglandFemaleHumansMaleMiddle AgedNational Health ProgramsPandemicsSARS-CoV-2State MedicineUnited KingdomCOVID‐19diabetic retinopathyimagingretinal screeningscreening intervalsight threatening diabetic retinopathyvisual loss

Identifiers

PMID39901468
PMCPMC12006553

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.